Beta-2 microglobulin (b2m) and b2m related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
CA 2495225 A1 · Owner: Genenews Corporation · Inventors: Zhang, Hongwei; Liew, Choong-Chin; Marshall, Wayne, E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the discovery of the role of beta-2 microglobulin (B2M) in the pathogenesis of osteoarthritis (OA) and the ability of B2M to inhibit chondrocyte proliferation. The invention further relates to the identification of genes regulated by B2M (the "B2M related genes").
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 27, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.